IL202720A - Promoteralsa casts for expression of alphavirus protein structures - Google Patents
Promoteralsa casts for expression of alphavirus protein structuresInfo
- Publication number
- IL202720A IL202720A IL202720A IL20272009A IL202720A IL 202720 A IL202720 A IL 202720A IL 202720 A IL202720 A IL 202720A IL 20272009 A IL20272009 A IL 20272009A IL 202720 A IL202720 A IL 202720A
- Authority
- IL
- Israel
- Prior art keywords
- alphavirus
- rna
- helper
- rna molecule
- replicon
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title claims abstract description 339
- 101710172711 Structural protein Proteins 0.000 title claims abstract description 125
- 230000014509 gene expression Effects 0.000 title description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 259
- 230000010076 replication Effects 0.000 claims abstract description 98
- 239000002773 nucleotide Substances 0.000 claims abstract description 65
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 65
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 50
- 108091081024 Start codon Proteins 0.000 claims abstract description 34
- 238000013518 transcription Methods 0.000 claims abstract description 19
- 230000035897 transcription Effects 0.000 claims abstract description 19
- 239000002245 particle Substances 0.000 claims description 119
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 239000013598 vector Substances 0.000 claims description 54
- 102000039446 nucleic acids Human genes 0.000 claims description 51
- 108020004707 nucleic acids Proteins 0.000 claims description 51
- 108090000565 Capsid Proteins Proteins 0.000 claims description 46
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 43
- 230000035772 mutation Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 13
- 108020005350 Initiator Codon Proteins 0.000 claims description 9
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 2
- 101710128560 Initiator protein NS1 Proteins 0.000 claims 1
- 101710144127 Non-structural protein 1 Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 description 100
- 108090000288 Glycoproteins Proteins 0.000 description 100
- 210000004027 cell Anatomy 0.000 description 98
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 70
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 70
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 70
- 210000000234 capsid Anatomy 0.000 description 64
- 235000018102 proteins Nutrition 0.000 description 41
- 239000012634 fragment Substances 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 37
- 108091026890 Coding region Proteins 0.000 description 35
- 102220076188 rs751198815 Human genes 0.000 description 28
- 230000006798 recombination Effects 0.000 description 26
- 238000005215 recombination Methods 0.000 description 26
- 241001068263 Replication competent viruses Species 0.000 description 25
- 108020004705 Codon Proteins 0.000 description 24
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 22
- 108030001720 Bontoxilysin Proteins 0.000 description 20
- 108090000848 Ubiquitin Proteins 0.000 description 19
- 102000044159 Ubiquitin Human genes 0.000 description 19
- 238000004806 packaging method and process Methods 0.000 description 19
- 210000003501 vero cell Anatomy 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 230000014616 translation Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 229960005486 vaccine Drugs 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 108091027544 Subgenomic mRNA Proteins 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 13
- 238000011144 upstream manufacturing Methods 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 241000710960 Sindbis virus Species 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000700618 Vaccinia virus Species 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000002741 site-directed mutagenesis Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000002349 favourable effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 210000003705 ribosome Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108091092724 Noncoding DNA Proteins 0.000 description 5
- 101800000980 Protease nsP2 Proteins 0.000 description 5
- 241000710961 Semliki Forest virus Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010087302 Viral Structural Proteins Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- -1 i.e. Proteins 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000710951 Western equine encephalitis virus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 101710201734 E3 protein Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 108091028733 RNTP Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101710132906 Structural polyprotein Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000230 ultraviolet fluorescence microscopy Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- MJWYCUZCRGLCBD-BGZMIMFDSA-N (4s)-4-amino-5-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O MJWYCUZCRGLCBD-BGZMIMFDSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100327537 Caenorhabditis elegans cgp-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 1
- 101100232687 Drosophila melanogaster eIF4A gene Proteins 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- HGCNKOLVKRAVHD-RYUDHWBXSA-N Met-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-RYUDHWBXSA-N 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 241001428748 Ockelbo virus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- APIAILHCTSBGLU-JYJNAYRXSA-N Pro-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@@H]2CCCN2 APIAILHCTSBGLU-JYJNAYRXSA-N 0.000 description 1
- GXWRTSIVLSQACD-RCWTZXSCSA-N Pro-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@@H]1CCCN1)O GXWRTSIVLSQACD-RCWTZXSCSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- WRUWXBBEFUTJOU-XGEHTFHBSA-N Thr-Met-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N)O WRUWXBBEFUTJOU-XGEHTFHBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 102100040396 Transcobalamin-1 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108010008118 glutamyl-leucyl-valyl-isoleucyl-serine Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 108010028403 hemagglutinin esterase Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010068488 methionylphenylalanine Proteins 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010950 spiking study Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663707P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/007701 WO2008156829A2 (en) | 2007-06-21 | 2008-06-20 | Promoterless cassettes for expression of alphavirus structural proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL202720A0 IL202720A0 (en) | 2011-08-01 |
| IL202720A true IL202720A (en) | 2013-10-31 |
Family
ID=40156867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL202720A IL202720A (en) | 2007-06-21 | 2009-12-14 | Promoteralsa casts for expression of alphavirus protein structures |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7850977B2 (OSRAM) |
| EP (2) | EP2947149B1 (OSRAM) |
| JP (3) | JP5602624B2 (OSRAM) |
| CN (1) | CN101802199B (OSRAM) |
| AU (1) | AU2008266807B2 (OSRAM) |
| CA (1) | CA2689588C (OSRAM) |
| DK (2) | DK2183368T3 (OSRAM) |
| ES (2) | ES2588906T3 (OSRAM) |
| IL (1) | IL202720A (OSRAM) |
| NZ (1) | NZ582495A (OSRAM) |
| PL (2) | PL2947149T3 (OSRAM) |
| WO (1) | WO2008156829A2 (OSRAM) |
| ZA (1) | ZA200909080B (OSRAM) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2947149T3 (pl) * | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
| EP2370584B1 (en) | 2008-12-01 | 2014-11-05 | Alphavax, Inc. | Use of microRNAs to control virus helper nucleic acids |
| AU2010234362B2 (en) | 2009-04-08 | 2015-11-26 | Alphavax, Inc. | Alphavirus replicon particles expressing TRP2 |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| DK4226941T3 (da) | 2010-08-31 | 2024-12-02 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til levering af immunogen-kodende rna |
| KR102266691B1 (ko) * | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| US10494421B2 (en) | 2014-02-10 | 2019-12-03 | Univercells Nv | System, apparatus and method for biomolecules production |
| PL3350333T3 (pl) | 2015-09-17 | 2022-03-07 | Modernatx, Inc. | Polinukleotydy zawierające region stabilizujący ogon |
| CN113181106A (zh) | 2016-01-11 | 2021-07-30 | 沃达瑞公司 | 微针组合物及其使用方法 |
| WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017162266A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| US10538786B2 (en) | 2016-04-13 | 2020-01-21 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| US12385034B2 (en) | 2016-06-24 | 2025-08-12 | Modernatx, Inc. | Methods and apparatus for filtration |
| MX2019004499A (es) * | 2016-10-17 | 2019-11-18 | Janssen Pharmaceuticals Inc Star | Sistemas de replicón de virus recombinante y usos de estos. |
| AU2017372731B2 (en) | 2016-12-05 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| JP2020518648A (ja) | 2017-05-08 | 2020-06-25 | グリットストーン オンコロジー インコーポレイテッド | アルファウイルス新生抗原ベクター |
| US20200283497A1 (en) * | 2017-09-13 | 2020-09-10 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing at cell receptor or an artificial t cell receptor |
| CA3075549A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
| CA3080427A1 (en) | 2017-11-06 | 2019-05-09 | Intervet International B.V. | Feline leukemia virus vaccine |
| WO2019086645A1 (en) | 2017-11-06 | 2019-05-09 | Intervet International B.V. | Rabies virus vaccine |
| US11167027B2 (en) | 2017-11-06 | 2021-11-09 | Intervet Inc. | Multivalent feline vaccine |
| EP3706788A1 (en) | 2017-11-06 | 2020-09-16 | Intervet International B.V. | Feline leukemia virus vaccine |
| BR112020011041A2 (pt) | 2017-12-04 | 2020-11-17 | Intervet International B.V. | vacina contra a doença de lyme canina |
| WO2019110481A1 (en) | 2017-12-04 | 2019-06-13 | Intervet International B.V. | Vaccination with replicon particles and oil adjuvant |
| JP7374893B2 (ja) | 2017-12-08 | 2023-11-07 | インターベット インターナショナル ベー． フェー． | ネコカリシウイルスワクチン |
| JP7427585B2 (ja) | 2017-12-15 | 2024-02-05 | インターベット インターナショナル ベー． フェー． | 多価ネコワクチン |
| CN118976103A (zh) | 2017-12-18 | 2024-11-19 | 英特维特国际股份有限公司 | 猪甲型流感病毒疫苗 |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| CA3089024A1 (en) | 2018-01-19 | 2019-07-25 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
| BR112021006614A2 (pt) | 2018-10-08 | 2021-07-20 | Janssen Pharmaceuticals, Inc. | replicons com base em alfavírus para administração de bioterápicos |
| CN113194989B (zh) | 2018-12-20 | 2024-01-30 | 英特维特国际股份有限公司 | 初免-强化免疫接种方案 |
| AU2020282369A1 (en) | 2019-05-30 | 2022-01-20 | Seattle Project Corp. | Modified adenoviruses |
| US11759515B2 (en) | 2020-03-09 | 2023-09-19 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| CN115867658A (zh) | 2020-04-17 | 2023-03-28 | Vlp治疗公司 | 冠状病毒疫苗 |
| AU2021264216A1 (en) | 2020-04-30 | 2022-11-10 | Vlp Therapeutics, Inc. | Cytokine immunotherapy |
| EP4149532A1 (en) | 2020-05-11 | 2023-03-22 | Intervet International B.V. | Feline severe acute respiratory syndrome coronavirus 2 vaccine |
| BR112022025678A2 (pt) | 2020-06-19 | 2023-01-17 | Intervet Int Bv | Vacina contra o vírus da influenza a suína compreendendo duas partículas de replicon de rna distintas |
| US20230265130A1 (en) | 2020-06-19 | 2023-08-24 | Intervet Inc. | Swine influenza a virus vaccine comprising a nucleic acid construct having a specific order of genes |
| CN115836082A (zh) | 2020-06-19 | 2023-03-21 | 英特维特国际股份有限公司 | 包含编码特定病毒谱系抗原的核酸构建体的甲型猪流感病毒疫苗 |
| EP4168429A1 (en) | 2020-06-19 | 2023-04-26 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| EP4210740A1 (en) | 2020-09-07 | 2023-07-19 | Intervet International B.V. | Ha stem vaccine for ha antibody-positive targets |
| EP4243864A1 (en) | 2020-11-12 | 2023-09-20 | Intervet International B.V. | Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof |
| US20250281597A1 (en) | 2021-10-25 | 2025-09-11 | Intervet Inc. | A vaccine for the protection of piglets against swine influenza a virus infection |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| NZ225583A (en) | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| US6770283B1 (en) * | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
| US20020102273A1 (en) * | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
| WO1994017813A1 (en) * | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
| RU2057377C1 (ru) | 1993-08-23 | 1996-03-27 | Уральский электрохимический комбинат | Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| CA2158937C (en) | 1993-09-15 | 2006-01-03 | Thomas W. Dubensky, Jr. | Recombinant alphavirus vectors |
| SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| FR2723849B1 (fr) * | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US5639650A (en) | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
| US6197879B1 (en) * | 1995-10-31 | 2001-03-06 | Henkel Corporation | Methods of preparing inorganic pigment dispersions |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| AU2809897A (en) | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
| US5853719A (en) * | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| JP2000514290A (ja) * | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| JP2965908B2 (ja) | 1996-07-05 | 1999-10-18 | 株式会社精工技研 | 調温液体シール手段を備える光ディスク成形用金型装置 |
| US5827658A (en) | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| US5726022A (en) | 1996-11-18 | 1998-03-10 | Lifespan Biosciences, Inc. | Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences |
| JP4492826B2 (ja) * | 1996-11-20 | 2010-06-30 | イントロジェン セラピューティクス，インコーポレイテッド | アデノウイルスベクターの産生および精製のための改良された方法 |
| FR2757169B1 (fr) * | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin |
| US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| US5958738A (en) | 1997-03-24 | 1999-09-28 | Roche Diagnostics Corporation | Procedure for subtractive hybridization and difference analysis |
| US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
| GB9716611D0 (en) | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
| AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
| GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| FI106618B (fi) | 1998-03-30 | 2001-03-15 | Sandvik Tamrock Oy | Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä |
| US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
| DE69942006D1 (de) | 1998-04-08 | 2010-03-25 | Univ North Carolina | Krebsimpfstoff enthaltend alphavirusrepliconpartikeln |
| WO1999061643A1 (en) | 1998-05-27 | 1999-12-02 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient |
| US7267823B2 (en) | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
| WO2000000616A2 (en) | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| US6770479B1 (en) | 1998-07-10 | 2004-08-03 | The United States Of America As Represented By The Secretary Of The Army | Anthrax vaccine |
| AU759461B2 (en) * | 1998-07-10 | 2003-04-17 | U.S. Medical Research Institute Of Infectious Diseases | Botulinum neurotoxin vaccine |
| WO2000002523A2 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases Department Of The Army | Vaccine against staphylococcus intoxication |
| EP1117430A1 (en) | 1998-10-05 | 2001-07-25 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
| WO2000039318A1 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| US6329201B1 (en) * | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| EP2206785A1 (en) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| DK1175497T3 (da) | 1999-04-14 | 2010-05-31 | Novartis Vaccines & Diagnostic | Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer |
| JP2003508056A (ja) | 1999-08-31 | 2003-03-04 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | アルファウイルス感染の抗体依存性増強（ａｄｅ） |
| EP1222299A1 (en) * | 1999-10-01 | 2002-07-17 | Genovo, Incorporated | Production of recombinant aav using adenovirus comprising aav rep/cap genes |
| US7115391B1 (en) * | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| CA2410948C (en) | 2000-05-31 | 2012-07-17 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
| WO2002003917A2 (en) | 2000-07-07 | 2002-01-17 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| AU2002227506A1 (en) | 2000-07-28 | 2002-02-13 | Visteon Global Technologies, Inc. | An air intake arrangement for an internal combustion engine |
| DE60130569D1 (de) | 2000-08-29 | 2007-10-31 | Wyeth Corp | Verpackung von replikon-partikeln eines positiv-strängigen rna-virus |
| AU2001290642A1 (en) * | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
| DE10049587A1 (de) * | 2000-10-06 | 2002-05-02 | Icon Genetics Ag | Vektorsystem für Pflanzen |
| DE10061150A1 (de) * | 2000-12-08 | 2002-06-13 | Icon Genetics Ag | Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen |
| US6800289B2 (en) | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
| US20030021766A1 (en) | 2001-01-12 | 2003-01-30 | Michael Vajdy | Nucleic acid mucosal immunization |
| DE10121283B4 (de) | 2001-04-30 | 2011-08-11 | Icon Genetics GmbH, 80333 | Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen |
| US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| JP4608210B2 (ja) | 2001-05-31 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | キメラアルファウイルスレプリコン粒子 |
| DE10143237A1 (de) * | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
| DE10143238A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente |
| EP1432791B2 (en) * | 2001-09-06 | 2013-10-23 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2003083065A2 (en) | 2002-03-25 | 2003-10-09 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
| JP3857195B2 (ja) * | 2002-07-09 | 2006-12-13 | 株式会社東芝 | 距離継電装置 |
| EP1583500A4 (en) * | 2002-11-13 | 2008-02-13 | Us Navy | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES AND PROTEIN IMMUNITY BY PRIMARY IMMUNIZATION WITH ALPHAVIRUS REPLICON VACCINES |
| EP1585812B1 (en) | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| EP2290054B1 (en) | 2002-12-13 | 2017-03-29 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| JP5016305B2 (ja) | 2003-03-20 | 2012-09-05 | アルファヴァックス，インコーポレイテッド | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 |
| US20060099587A1 (en) * | 2003-06-20 | 2006-05-11 | Johnston Robert E | Alphavirus vectors having attentuated virion structural proteins |
| ATE432285T1 (de) | 2003-07-11 | 2009-06-15 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| EP1687033A4 (en) * | 2003-11-12 | 2008-06-11 | Us Navy | IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE |
| US7078087B2 (en) * | 2003-12-31 | 2006-07-18 | Kimberly-Clark Worldwide, Inc. | Wipes with an edge treatment along a leading edge portion |
| CA2567254C (en) | 2004-05-18 | 2012-03-13 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| EP1856250B1 (en) * | 2005-02-15 | 2013-07-24 | The University of North Carolina At Chapel Hill | New live virus vaccines |
| WO2008033966A2 (en) * | 2006-09-12 | 2008-03-20 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
| PL2947149T3 (pl) | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
| CA2910235C (en) * | 2008-01-24 | 2021-07-06 | Scott C. Weaver | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof |
-
2008
- 2008-06-20 PL PL15173487T patent/PL2947149T3/pl unknown
- 2008-06-20 US US12/143,320 patent/US7850977B2/en active Active
- 2008-06-20 US US12/665,497 patent/US8460913B2/en active Active
- 2008-06-20 NZ NZ582495A patent/NZ582495A/en unknown
- 2008-06-20 ES ES08825920.5T patent/ES2588906T3/es active Active
- 2008-06-20 ES ES15173487.8T patent/ES2670813T3/es active Active
- 2008-06-20 EP EP15173487.8A patent/EP2947149B1/en active Active
- 2008-06-20 AU AU2008266807A patent/AU2008266807B2/en active Active
- 2008-06-20 CN CN2008801036605A patent/CN101802199B/zh active Active
- 2008-06-20 DK DK08825920.5T patent/DK2183368T3/en active
- 2008-06-20 CA CA2689588A patent/CA2689588C/en active Active
- 2008-06-20 DK DK15173487.8T patent/DK2947149T3/en active
- 2008-06-20 EP EP08825920.5A patent/EP2183368B1/en active Active
- 2008-06-20 JP JP2010513254A patent/JP5602624B2/ja active Active
- 2008-06-20 WO PCT/US2008/007701 patent/WO2008156829A2/en not_active Ceased
- 2008-06-20 PL PL08825920.5T patent/PL2183368T3/pl unknown
-
2009
- 2009-12-14 IL IL202720A patent/IL202720A/en active IP Right Grant
- 2009-12-18 ZA ZA200909080A patent/ZA200909080B/xx unknown
-
2014
- 2014-08-20 JP JP2014167257A patent/JP5995926B2/ja active Active
-
2016
- 2016-08-23 JP JP2016162382A patent/JP2016198114A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008156829A3 (en) | 2009-03-12 |
| DK2947149T3 (en) | 2018-06-06 |
| AU2008266807B2 (en) | 2012-08-16 |
| US20090075384A1 (en) | 2009-03-19 |
| JP5995926B2 (ja) | 2016-09-21 |
| CA2689588C (en) | 2016-08-23 |
| PL2183368T3 (pl) | 2016-12-30 |
| ES2670813T3 (es) | 2018-06-01 |
| JP2010530245A (ja) | 2010-09-09 |
| WO2008156829A2 (en) | 2008-12-24 |
| US8460913B2 (en) | 2013-06-11 |
| CN101802199B (zh) | 2012-08-22 |
| US20100183665A1 (en) | 2010-07-22 |
| EP2947149A1 (en) | 2015-11-25 |
| NZ582495A (en) | 2012-05-25 |
| EP2947149B1 (en) | 2018-02-28 |
| HK1217216A1 (en) | 2016-12-30 |
| DK2183368T3 (en) | 2016-09-05 |
| CA2689588A1 (en) | 2008-12-24 |
| CN101802199A (zh) | 2010-08-11 |
| JP2014230544A (ja) | 2014-12-11 |
| EP2183368A4 (en) | 2011-04-13 |
| US7850977B2 (en) | 2010-12-14 |
| JP2016198114A (ja) | 2016-12-01 |
| EP2183368B1 (en) | 2016-08-10 |
| IL202720A0 (en) | 2011-08-01 |
| ZA200909080B (en) | 2010-09-29 |
| ES2588906T3 (es) | 2016-11-07 |
| AU2008266807A1 (en) | 2008-12-24 |
| PL2947149T3 (pl) | 2018-09-28 |
| EP2183368A2 (en) | 2010-05-12 |
| JP5602624B2 (ja) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7850977B2 (en) | Promoterless cassettes for expression of alphavirus structural proteins | |
| US10570416B2 (en) | TC-83-derived alphavirus vectors, particles and methods | |
| KR101518309B1 (ko) | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 | |
| HK1217216B (en) | Alphavirus replicon particles for use in vaccination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |